A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (NCT04929223)
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
🩺 Plain-English Summary (8th-Grade Level)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Who can join: Review the eligibility criteria below.
Location: UAB Comprehensive Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (84 Sites)
Showing the first 25 of 84 sites.
- UAB Comprehensive Cancer Center — Birmingham, Alabama
- Mayo Clinic Arizona — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
- cCare — Encinitas, California
- USC Norris Cancer Center — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Stanford Cancer Center — Stanford, California
- University of Colorado Cancer Center — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Eastern Ct Hema/Onco Assoc — Norwich, Connecticut
- Mayo Clinic in Florida — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Illinois Cancer Specialists — Arlington Heights, Illinois
- Mary Bird Perkins Cancer Ctr — Baton Rouge, Louisiana
- Massachusetts General Hospital — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- New York Cancer & Blood Specialists - New Hyde Park — New Hyde Park, New York
- New York Cancer and Blood Specialists-Central Park Hematology & Oncology — New York, New York
- New York Cancer & Blood Specialists — Port Jefferson Station, New York
- New York Cancer & Blood Specialists - Bronx — The Bronx, New York
- Duke University Medical Center — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Colorectal Cancer
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Phoenix, Arizona
- Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer — Toronto, Ontario
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) — Los Angeles, California
- A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer — Duarte, California
- A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer — Los Angeles, California
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Phoenix, Arizona
Explore by condition: All Metastatic Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.